Home/Pipeline/Epeleuton

Epeleuton

Sickle Cell Disease

Phase 2Active

Key Facts

Indication

Sickle Cell Disease

Phase

Phase 2

Status

Active

Company

Afimmune

About Afimmune

Afimmune is an Irish clinical-stage biotech developing novel small molecule drugs for rare and cardiometabolic diseases. Its lead program, Epeleuton, is a next-generation synthetic omega-3 fatty acid in clinical trials for Sickle Cell Disease (SCD), targeting both red blood cell health and vascular inflammation. Founded in 2015 by industry veterans with deep experience in clinical research, the company is privately held and appears to be pre-revenue, advancing its pipeline through clinical development. Afimmune's strategy focuses on addressing significant unmet needs in SCD, a serious inherited disorder with limited treatment options and high morbidity.

View full company profile

Therapeutic Areas

Sickle Cell Disease Rare Diseases Inflammatory Diseases

Other Sickle Cell Disease Drugs

Drug	Company	Phase	Status
ANXV	Annexin Pharmaceuticals	Research	Identified
Oxbryta® (voxelotor)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
CT-101	Cetya Therapeutics	Pre-clinical	Active - Lead candidate nominated
Endari (L-glutamine oral powder)	Emmaus Life Sciences	Approved	Commercial/Marketed
Undisclosed	Biossil	Phase 2/3	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Ramatroban (KAR101)	KARE Biosciences	Preclinical	Active
Digital Model for Sickle Cell Disease	Koneksa Health	Development/Validation	Active
ILX-002	Illexcor Therapeutics	Pre-clinical	Active
CLY-124	Cellarity	Phase 1	Active
AB1	AkiraBio	Pre-clinical	Active
Oral Decitabine/Tetrahydrouridine	Novo Nordisk	Phase 2	Active